News
Tebubio and Apricell Announce Partnership to Advance 3D Cell Culture and Organoid Research
A new partnership has been established between Tebubio, a leading distributor of life science research reagents and services, and Apricell, an innovative company specializing in 3D cell culture technologies.
Tebubio Partners with 4Dcell to Expand Access to Advanced 3D Cell Culture, “NAMs”, Technologies
Tebubio, a European distributor of life science research reagents and services, partners with 4Dcell, a pioneering company specializing in the design of innovative cell culture environments. This collaboration
In the Press: In Vitro Oncology Models as an Alternative to Animal Models
Tebubio’s Célia Bosso-Lefevre, PhD, discusses in Technology Networks how in vitro oncology models provide ethical, predictive alternatives to animal testing and accelerate cancer research.
In the Press: Lipid Nanoparticules (LNPs) for Nucleic Acid Delivery
Discover how scientists use lipid nanoparticles (LNPs) to visualize RNA delivery in cancer research, paving the way for personalised mRNA-based oncology treatments.
In the Press: What Role is Precision Medicine Playing in Transforming Cancer Treatment, and How Are Developers Adapting?
Insights from our Senior Project Manager, Dr. Erica Cirri, on how precision medicine, CRISPR, and mRNA are transforming cancer treatment with more targeted and effective therapies.
In the Press: Driving Innovation in RNA Therapeutics - Tebubio’s Tailored CRS Services Featured in Inside Medicon Valley 2025/2026
Tebubio featured in Inside Medicon Valley 2025/2026 for its Contract Research Services expertise in RNA therapeutics, supporting mRNA production, LNP formulation, and delivery solutions.
abberior & Tebubio join Forces to Expand Access to Fluorescent Probes in Europe
Tebubio is now collaborating with abberior!
This partnership makes bright and photostable dyes more accessible to researchers in Life Sciences and advanced microscopy.
PRESS RELEASE from abberior
In the Press: What New Opportunities are Emerging for mRNA Technology, and How is the Portfolio of Applications Expanding Beyond Vaccines?
Discover new opportunities for mRNA technology in oncology, rare diseases, and genome editing. Featuring expert insights from Tebubio's Erica Cirri in Pharma’s Almanac.
In the Press: Advances in RNA Vaccine Development and Delivery: A Multifaceted Approach to Infectious Diseases and Cancer
Explore the latest RNA vaccine and delivery breakthroughs in Tebubio’s IBI article. Discover how saRNA, circRNA, and LNPs are transforming infectious disease and cancer treatments.
In the Press: The RNA Revolution – Strategic Partnerships Driving the Future of Vaccine Development
Accelerating the RNA Revolution: Partnerships Fuel Progress
In the RNA field, many companies are facing challenges when advancing research projects due to time, expertise, and resource constraints. Many
Pearl BioSystem and Tebubio Announce Availability of in perlo™ 3D Screening Products in Europe
Pearl BioSystem, a pioneer in next-generation 3D cell culture technologies, is pleased to announce that it’s in perlo™ product line is now available across Europe through Tebubio, a leading European
Important Notice: Delivery Suspension in Spain and Portugal
Important Notice: Delivery Suspension in Spain and Portugal
In light of the challenging circumstances caused by the widespread power outage, we at Tebubio wish to express our deepest compassion and solidarity